DFX Intelligence
Private Credit Intelligence
The capital structure graph behind private markets. Who lent, to whom, under which sponsor, through which facility, how large the piece was, when it matures and what changed, with a filing behind every number. A BDC piece is that BDC's piece, a sum of pieces is a lower bound, and a sponsor is named with the evidence that names it.
The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.
Borrower
4• M•••••••• T••••••••• I••
Drug Discovery & Developmentgroup grade Aon a schedule nowsponsor V••••• G••••• I•••••••• L• carried
Principal held
at least $15.2M
sum of BDC pieces, a lower bound
Fair value
$15.0M
100c on cost, debt pieces
Unfunded
$22.8M
commitments not yet drawn
BDC lenders
1
1 on the latest quarter
Facilities
1
1 equity pieces beside them
Next maturity
Jun 1, 2031
no dated debt inside 24 months
On the tape since
Dec 31, 2025
latest Jun 30, 2026
Events
1
dated, non-routine
Capital structure as the BDCs see it
latest quarter end Jun 30, 2026
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien | at least $15.2M | 100c | S+200 bp | Jun 1, 2031 | 1 |
Equity pieces beside the debt: other (n/a fair value, 1 BDC)
Lenders
every BDC piece at the latest quarter end
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| H••••••• C••••••• I••• | term loan first lien Senior Secured, June 2031, Prime + 2.00%, Floor rate 8.75%, Cap rate 9.50%, 6.50% Exit Fee | $15.2M | $15.0M 100c | S+200 bp |
| H••••••• C••••••• I••• | unstated lien unstated | n/a | n/a |
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2026 | 1 | $15.2M | $15.0M | 100c | 0 |
| Dec 31, 2025 | 1 | $0 | $0 | n/a | 0 |
What changed
- New borrower on a BDC scheduleDec 31, 2025
Sponsor
- V••••• G••••• I•••••••• L•
- the sponsor's own portfolio page lists a company of this nameestimatedvikingglobal.com"portfolio card on https://vikingglobal.com/private-equity-portfolio/: 4• M•••••••• T••••••••• | Clinical-stage biotherapeutics company focused on harnessing the power of directed evolution for targete"
Identity
- Group key
- 4D MOLECULAR THERAPEUTICSderivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 1 BDCderived
- Industry
- Drug Discovery & Developmentreportedas one filer wrote it